Perhaps buoyed by a string of positive data, 2004 Fierce 15 [1] winner Synta Pharmaceuticals is filing a $115 million IPO despite the risky biotech IPO climate. The Lexington, MA biotech has yet to determine the number of shares to be offered and the price range for the offering. Earlier this month the FDA granted Synta fast-track status for its lead oncology drug candidate, STA-4783 [2]. Synta is developing small molecule drugs for a number of indications, including cancer and chronic inflammatory diseases.
- see the company press release [3]
Related Articles:
Synta gets fast track for cancer therapy. Report [4]
Synta trial hits endpoint. Report [2]
Biotech IPOs losing their attraction. Report [5]
Links:
[1] http://www.fiercebiotech.com/Fierce15/2004/#Synta
[2] http://www.fiercebiotech.com/story/spotlight-synta-trial-hits-endpoint/2006-09-15
[3] http://www.fiercebiotech.com/node/4679
[4] http://www.fiercebiotech.com/story/spotlight-synta-gets-fast-track-for-cancer-therapy/2006-11-15
[5] http://www.fiercebiotech.com/story/biotech-ipos-losing-their-attraction/2006-05-15